BAX vs VTRS vs RVP Stock Comparison

Baxter International, Viatris and Retractable Technologies Prices as of Oct 29, 2026 Peers: Industry group
BAX Baxter International Inc
$23.49 0.0% 1M +4.8% 1Y
Market cap
$12.15B
P/E
–
Revenue (TTM)
$11.61B
Div. yield
0.17%
Medical Supplies Healthcare
1 win
VTRS Viatris Inc
$19.20 +6.0% 1M +87.0% 1Y
Market cap
$22.05B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
2.50%
Generic Drugs Healthcare
9 wins

Head to Head

11 decided of 12

Viatris leads on 9 of the 12 questions below (Viatris 9, Baxter International 1, Retractable Technologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBAXVTRSRVPLeader
Larger companyMarket capitalisation $12.15B $22.05B $17.36M VTRS
Cheaper on earningsLower P/E, profitable companies only -16.8x -54.4x -4.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 11.9x 7.3x — VTRS
Faster revenue growthRevenue growth, trailing twelve months +5.3% +4.4% -11.2% BAX
More profitableNet margin, trailing twelve months -6.2% -2.8% -10.6% VTRS
Better return on capitalReturn on invested capital -1.4% -0.2% -31.4% VTRS
Less leveragedLower net debt / EBITDA 9.0x 4.6x 2.6x RVP
Higher dividend yieldTrailing dividend yield 0.17% 2.50% — VTRS
Better 1-year returnPrice return, last 12 months +4.8% +87.0% -35.5% VTRS
Better 5-year returnAnnualised price return, 5 years -21.5%/yr +7.5%/yr -42.8%/yr VTRS
Less volatileAnnualised volatility, 1 year 45.1% 32.4% 40.2% VTRS
Higher overall scoreMean of the five percentile scores vs peers 44/100 66/100 53/100 VTRS

Percentile Scorecard

BAXVTRSRVP

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBAXVTRSRVP
Valuation 89 #25 of 227 93 #42 of 624 72 #64 of 227
Growth 14 #187 of 218 49 #308 of 601 34 #145 of 218
Profitability 66 #69 of 202 82 #100 of 541 40 #121 of 202
Financial Health 19 #189 of 233 22 #502 of 647 64 #84 of 233
Shareholder Returns 33 #87 of 130 85 #54 of 359 –
Overall 44 66 53
  • BAX ranked among 247 companies in Medical Devices and Diagnostics
  • VTRS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • RVP ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBAXVTRSRVPSPY
1 month 0.0%+6.0%-15.9% +0.7%
3 months -12.2%+8.1%-14.7% +3.7%
6 months +33.6%+28.5%-8.2% +7.1%
Year to date +22.9%+54.2%-24.9% +12.8%
1 year +4.8%+87.0%-35.5% +11.9%
3 years -26.7%+117.2%-47.3% +85.2%
3 years, per year -9.8%+29.5%-19.2% +22.8%
5 years -70.3%+43.8%-93.9% +67.6%
5 years, per year -21.5%+7.5%-42.8% +10.9%
10 years -50.2%-48.4%-76.8% +262.0%
10 years, per year -6.7%-6.4%-13.6% +13.7%

Risk

MeasureBAXVTRSRVPSPY
Volatility, 1Y 45.1%32.4%40.2% 12.7%
Downside volatility, 1Y 49.5%29.8%45.0% 12.6%
Beta vs S&P 500, 1Y 1.180.700.16 1.00
Return / volatility, 1Y 0.112.69-0.88 0.94
Max drawdown, 5Y -82.3%-52.9%-94.0% -25.4%
From 52-week high -17.1%0.0%-35.5% -1.2%
52-week high $28.35$19.20$0.90 $779.14
52-week low $15.80$10.11$0.58 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBAXVTRSRVP
P/E now vs peer median -16.8xmedian 28.7x -54.4xmedian 17.8x -4.8xmedian 28.7x
P/S now vs peer median 1.0xmedian 3.0x 1.5xmedian 9.1x 0.5xmedian 3.0x
EV/EBITDA now vs peer median 25.6xmedian 17.8x 12.7xmedian 15.0x 1.5xmedian 17.8x
P/FCF now vs peer median 10.5xmedian 26.4x 11.3xmedian 21.7x -3.4xmedian 26.4x
P/B now vs peer median 1.9xmedian 2.4x 1.5xmedian 2.2x 0.2xmedian 2.4x
PEG now vs peer median 0.53median 0.99 1.78median 0.35 0.22median 0.99

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBAXVTRSRVP
Revenue $11.61B $14.74B $33.90M
Gross profit $3.49B $5.13B -$491.51K
Operating income -$221.00M -$87.30M -$22.68M
Net income -$723.00M -$410.70M -$3.37M
Free cash flow $1.16B $1.95B -$5.11M
R&D $519.00M $1.02B $682.03K
EPS (diluted) $-1.39 $-0.35 $-0.12
Cash & equivalents $1.98B $886.50M $2.64M
Total debt $8.60B $13.35B $3.40M
Shares (diluted) 520.00M 1.16B 29.94M
Enterprise value $4.01B $17.06B -$129.04M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBAXVTRSRVP
P/E -16.8x -54.4x -4.8x
P/FCF 10.5x 11.3x -3.4x
P/Operating cash flow 7.3x 9.5x -3.5x
P/S 1.0x 1.5x 0.5x
P/B 1.9x 1.5x 0.2x
P/Tangible book 4.7x 37.8x 0.2x
EV/EBITDA 25.6x 12.7x 1.5x
EV/EBIT -84.9x -395.4x 1.0x
EV/Revenue 1.6x 2.3x -0.6x
EV/FCF 16.2x 17.7x 4.3x
EV/Operating cash flow 11.3x 14.8x 4.4x
PEG (3Y EPS CAGR) 0.53 1.78 0.22

Growth

14 metrics
MetricBAXVTRSRVP
Revenue growth (1Y) 5.3% 4.4% -11.2%
Revenue CAGR (3Y) 0.7% -1.9% -14.7%
Gross profit growth (1Y) -7.1% -0.7% 81.2%
Gross profit CAGR (3Y) -7.7% -6.0% -26.8%
Operating income growth (1Y) -136.3% 96.6% -2.3%
Operating income CAGR (3Y) 4.2% -27.6% -11.7%
Net income growth (1Y) -112.0% 88.2% 61.4%
Net income CAGR (3Y) -31.6% -30.5% -23.9%
EPS growth (1Y) -109.6% 88.1% 59.8%
EPS CAGR (3Y) -31.5% -30.6% -21.9%
Operating cash flow growth (1Y) 97.4% 12.9% 58.8%
Operating cash flow CAGR (3Y) 0.6% -3.0% -16.8%
Free cash flow growth (1Y) 243.5% 11.6% 62.3%
Free cash flow CAGR (3Y) -5.0% -3.6% 20.0%

Profitability

14 metrics
MetricBAXVTRSRVP
Gross margin 30.1% 34.8% -1.4%
EBITDA margin 6.3% 18.4% -43.9%
Operating margin -1.9% -0.6% -66.9%
Pretax margin -1.6% -4.5% -9.9%
Net margin -6.2% -2.8% -10.6%
FCF margin 10.0% 13.3% -15.1%
Operating cash flow margin 14.3% 15.8% -14.6%
Return on equity -11.4% -2.8% -4.7%
Return on assets -3.7% -1.1% -2.4%
Return on invested capital -1.4% -0.2% -31.4%
Return on capital employed -1.4% -0.3% -18.0%
Asset turnover 0.6x 0.4x 0.2x
Cash conversion (OCF / net income) -2.3x -5.7x 1.5x
Stock comp / revenue 0.9% 1.2% –

Financial Health

11 metrics
MetricBAXVTRSRVP
Debt / assets 44.3% 38.1% 0.5%
Debt / equity 1.3x 0.9x 0.0x
Net debt / EBITDA 9.0x 4.6x 2.6x
Debt / FCF 7.4x 6.8x -0.1x
Liabilities / assets 66.5% 59.3% 48.6%
Equity / assets 33.5% 40.7% 51.4%
Interest coverage – -0.2x -278.8x
Current ratio 1.8x 1.6x 4.9x
Quick ratio 1.0x 0.7x 3.7x
Cash ratio 0.5x 0.1x 3.0x
Altman Z-score 2.33 1.16 0.43

Shareholder Returns

7 metrics
MetricBAXVTRSRVP
Dividend yield 0.2% 2.5% –
Net buyback yield -0.2% 1.4% –
Shareholder yield 0.0% 3.9% –
Payout ratio (earnings) -14.1% – –
Payout ratio (FCF) 8.8% – –
Dividend growth (1Y) -75.0% – –
Dividend CAGR (3Y) -44.1% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBAXVTRSRVP
Forward P/E 11.9xFY2026 7.3xFY2026 –
EPS, next fiscal year $1.98FY2026 $2.62FY2026 –
EPS growth, next FY -10.4%FY2026 +11.5%FY2026 –
EPS growth, the year after -3.5% -1.5% –
Revenue, next fiscal year $11.05BFY2026 $15.31BFY2026 –
Revenue growth, next FY -1.7%FY2026 +7.0%FY2026 –
Revenue growth, the year after +11.7% -4.8% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBAXVTRSRVP
Held by institutions 100.0% 89.9% 8.8%
Institutions holding 691 1,030 32
Change in shares held, QoQ +5.2% +5.6% +5.9%
Institutions buying 359 488 10
Institutions selling 193 318 4
Buyers to sellers 1.86 1.53 2.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BAXVTRSRVP
BAX 1.00 0.31 0.03
VTRS 0.31 1.00 0.07
RVP 0.03 0.07 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BAX, VTRS and RVP?

Viatris (VTRS) is the largest by market capitalisation: Baxter International (BAX) $12.15B, Viatris (VTRS) $22.05B, Retractable Technologies (RVP) $17.36M.

Which company is growing faster?

Baxter International (BAX) grew revenue fastest over the trailing twelve months: Baxter International (BAX) +5.3%, Viatris (VTRS) +4.4%, Retractable Technologies (RVP) -11.2%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Baxter International (BAX) -6.2%, Viatris (VTRS) -2.8%, Retractable Technologies (RVP) -10.6%). On return on invested capital, Viatris (VTRS) leads (Baxter International (BAX) -1.4%, Viatris (VTRS) -0.2%, Retractable Technologies (RVP) -31.4%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Baxter International (BAX) +4.8%, Viatris (VTRS) +87.0%, Retractable Technologies (RVP) -35.5%. Over five years, Viatris (VTRS) compounded fastest (Baxter International (BAX) -21.5%/yr, Viatris (VTRS) +7.5%/yr, Retractable Technologies (RVP) -42.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Viatris (VTRS) has the highest dividend yield: Baxter International (BAX) 0.17%, Viatris (VTRS) 2.50%. Retractable Technologies (RVP) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Baxter International (BAX) 45.1%, Viatris (VTRS) 32.4%, Retractable Technologies (RVP) 40.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BAX, VTRS and RVP?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.